Table 4.

Risk of prostate cancer death within PSA subgroups split by risk from the four kallikrein panel

	N	Prostate cancer death	Reclassified	5-yr risk	10-yr risk	15-yr risk	20-yr risk
Men providing a blood sample at age 60–73 yr
PSA ≥ 2.0 ng/ml	1825	191		0.80 (0.45–1.35)	3.00 (2.22–3.95)	7.73 (6.39–9.23)	14.80 (12.72–17.04)
Panel risk
<6.0%	664	13	36%	0 (NA)	0.17 (0.01–1.22)	1.04 (0.35–2.49)	3.33 (1.72–5.79)
≥6.0%	1160	178	64%	1.27 (0.70–2.13)	4.64 (3.42–6.11)	11.61 (9.56–13.86)	21.49 (18.39–24.76)
<7.5%	842	24	46%	0 (NA)	0.55 (0.16–1.45)	1.70 (0.85–3.05)	4.24 (2.64–6.40)
≥7.5%	983	167	54%	1.49 (0.82–2.51)	5.12 (3.74–6.80)	13.00 (10.65–15.59)	24.21 (20.62–27.98)
<10%	1075	37	59%	0 (NA)	0.86 (0.38–1.71)	2.16 (1.28–3.41)	5.12 (3.54–7.09)
≥10%	750	154	41%	1.92 (1.06–3.23)	5.99 (4.30–8.06)	15.59 (12.69–18.76)	28.87 (24.41–33.48)
Men providing a blood sample at age 45–59 yr
PSA ≥ 1.5 ng/ml	1184	53		0 (NA)	0.45 (0.16–1.09)	2.32 (1.49–3.44)	4.86 (3.57–6.43)
Panel risk
<6.0%	858	22	73%	0 (NA)	0 (NA)	0.97 (0.40–2.03)	2.63 (1.56–4.17)
≥6.0%	326	31	27%	0 (NA)	1.63 (0.54–3.86)	5.77 (3.33–9.14)	10.70 (7.11–15.11)
<7.5%	962	28	82%	0 (NA)	0.22 (0.04–0.89)	1.21 (0.59–2.24)	3.11 (1.99–4.62)
≥7.5%	222	25	18%	0 (NA)	1.43 (0.31–4.37)	6.87 (3.70–11.36)	12.16 (7.62–17.83)
<10%	1056	32	89%	0 (NA)	0.20 (0.03–0.81)	1.44 (0.77–2.46)	3.30 (2.19–4.76)
≥10%	128	21	11%	0 (NA)	2.41 (0.50–7.29)	8.89 (4.32–15.52)	16.32 (9.68–24.47)

NA = not available; PSA = prostate-specific antigen.